Median overall survival of all 211 patients was 49.3 months.
所有211名患者的中位总存活数是49.3个月。
But median overall survival, a secondary end point, was 20.5 months in the combination group and 20.6 months in the monotherapy group.
但中位总生存期,次要观察终点,联合组为20.5个月,而单药治疗组为20.6个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
所有患者中位随访时间35.8个月,80例出现复发或转移,40例死亡,中位生存期未达到,中位无疾病生存期(DFS)为24.1个月。
应用推荐